KR20230154239A - 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체 - Google Patents

항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체 Download PDF

Info

Publication number
KR20230154239A
KR20230154239A KR1020237033840A KR20237033840A KR20230154239A KR 20230154239 A KR20230154239 A KR 20230154239A KR 1020237033840 A KR1020237033840 A KR 1020237033840A KR 20237033840 A KR20237033840 A KR 20237033840A KR 20230154239 A KR20230154239 A KR 20230154239A
Authority
KR
South Korea
Prior art keywords
antibody
antibody fragment
seq
region
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033840A
Other languages
English (en)
Korean (ko)
Inventor
스테판 슈타이들
스테판 헤르틀
라이너 박스해머
Original Assignee
모르포시스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게 filed Critical 모르포시스 아게
Publication of KR20230154239A publication Critical patent/KR20230154239A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020237033840A 2021-03-01 2022-03-01 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체 Pending KR20230154239A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21159860 2021-03-01
EP21159860.2 2021-03-01
PCT/EP2022/055080 WO2022184676A1 (en) 2021-03-01 2022-03-01 Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection

Publications (1)

Publication Number Publication Date
KR20230154239A true KR20230154239A (ko) 2023-11-07

Family

ID=74844778

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033840A Pending KR20230154239A (ko) 2021-03-01 2022-03-01 항체-매개 이식 거부의 치료에 사용하기 위한 항-cd38 항체

Country Status (12)

Country Link
US (1) US20240228654A9 (cg-RX-API-DMAC10.html)
EP (1) EP4301779A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024507986A (cg-RX-API-DMAC10.html)
KR (1) KR20230154239A (cg-RX-API-DMAC10.html)
AU (1) AU2022230717A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023016352A2 (cg-RX-API-DMAC10.html)
CA (1) CA3209172A1 (cg-RX-API-DMAC10.html)
CL (1) CL2023002495A1 (cg-RX-API-DMAC10.html)
IL (1) IL304692A (cg-RX-API-DMAC10.html)
MX (1) MX2023009868A (cg-RX-API-DMAC10.html)
TW (1) TW202302642A (cg-RX-API-DMAC10.html)
WO (1) WO2022184676A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202545561A (zh) * 2024-01-16 2025-12-01 德商莫菲西斯有限責任公司 抗體的高度濃縮液體製劑

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
EP2915820A1 (en) 2004-02-06 2015-09-09 MorphoSys AG Anti-CD38 human antibodies and uses therefor
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
CN101287764B (zh) 2005-10-12 2013-11-13 莫佛塞斯公司 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
EP3313441B1 (en) 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
EP3434692A1 (en) 2017-07-24 2019-01-30 Encefa Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases
WO2020185672A1 (en) 2019-03-08 2020-09-17 Cedars-Sinai Medical Center Anti-cd38 agents for desensitization and treatment of antibody-mediated rejection of organ transplants
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物

Also Published As

Publication number Publication date
WO2022184676A1 (en) 2022-09-09
TW202302642A (zh) 2023-01-16
BR112023016352A2 (pt) 2023-10-03
IL304692A (en) 2023-09-01
CA3209172A1 (en) 2022-09-09
EP4301779A1 (en) 2024-01-10
US20240228654A9 (en) 2024-07-11
CL2023002495A1 (es) 2023-12-29
US20240132618A1 (en) 2024-04-25
AU2022230717A1 (en) 2023-09-14
JP2024507986A (ja) 2024-02-21
MX2023009868A (es) 2023-08-29

Similar Documents

Publication Publication Date Title
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
KR101632775B1 (ko) 항-ｃｄ４０ 항체의 침묵 ｆｃ 변이체
HK1254289A1 (zh) 调控免疫反应的方法及抗体
CN113574071B (zh) 用于治疗自身抗体介导的自身免疫疾病的抗-cd38抗体及其药物组合物
JP2025184966A (ja) 抗ＳＩＲＰｇ抗体の新規の使用
KR20140116525A (ko) 항cxcr3 항체
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
TW201943731A (zh) 用於預防移植物排斥之抗cd40抗體
WO2019070047A1 (ja) 二重特異性抗体
US20240109977A1 (en) Anti-cd38 antibodies and their uses
JP2024535053A (ja) Ｖｉｓｔａ抗原結合性分子を使用する、がんの処置および防止
US20240228654A9 (en) Anti-cd38 antibodies for use in the treatment of antibody-mediated transplant rejection
TWI790193B (zh) 調控免疫反應之方法及抗體
CN116635422A (zh) 抗cd38抗体及其用途
CN116997570A (zh) 用于治疗抗体介导的移植排斥的抗cd38抗体
RU2809565C2 (ru) Антитела к CD38 и фармацевтические композиции на их основе для лечения аутоиммунного заболевания, опосредованного аутоантителами
CN113557244A (zh) 预防或治疗移植物抗宿主病(GvHD)的抗CCR7 mAb的用途
HK40099176A (en) Anti-cd 38 antibodies and their uses
WO2026080575A1 (en) Anti-cd38 antibodies and their uses
TWI677505B (zh) 抗ｃｄ２６抗體及其用途
HK40061358A (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
HK40061358B (en) Anti-cd38 antibodies and pharmaceutical compositions thereof for the treatment of autoantibody-mediated autoimmune disease
EA050337B1 (ru) Применение мат против ccr7 для предотвращения или лечения реакции "трансплантат против хозяина" (ртпх)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231004

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250224

Comment text: Request for Examination of Application